Shweta S Namjoshi
Pediatric Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Shweta S Namjoshi’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A123822 · Current
Licensed to practise in California · since 2012 · expires 2026-12-31 · Pennsylvania State University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$38,717 in 2024
Medicaid paid $38,717 for 318 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 210 | $33,920 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $2,263 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 47 | $1,477 |
| Service | 31 | $1,057 |
| 2024 | 318 | 4 | 24 | $38,717 |
| 2023 | 364 | 4 | 25 | $36,442 |
| 2022 | 74 | 1 | 16 | $10,349 |
| 2021 | 254 | 4 | 23 | $29,280 |
| 2020 | 297 | 3 | 18 | $30,614 |
| 2019 | 122 | 2 | 26 | $8,561 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 225 | $30,625 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 57 | $2,171 |
| Service | 58 | $1,978 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $1,669 |
2022
| Long return visit (40+ min) | 74 | $10,349 |
2021
| Long return visit (40+ min) | 204 | $26,485 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 23 | $1,384 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 13 | $934 |
| Service | 14 | $477 |
2020
| Long return visit (40+ min) | 145 | $17,129 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 128 | $9,384 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 24 | $4,101 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 105 | $6,735 |
| Long return visit (40+ min) | 17 | $1,827 |
Money from drug and device companies
$4,853 in 2025
| 2025 | 1 | 7 | $3,000 | $4,853 |
| 2023 | 1 | 2 | None | $118 |
| 2022 | 1 | 1 | $2,800 | $2,800 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcresta Therapeutics | Relizorb | $4,853 | 7 payments
|
See all 7 published payments
| Alcresta Therapeutics | Meals · 2025-06-10 | Relizorb | $55 |
| Alcresta Therapeutics | Meals · 2025-06-10 | Relizorb | $66 |
| Alcresta Therapeutics | Meals · 2025-06-10 | Relizorb | $125 |
| Alcresta Therapeutics | Honoraria · 2025-06-10 | Relizorb | $3,000 |
| Alcresta Therapeutics | Travel · 2025-06-10 | Relizorb | $220 |
| Alcresta Therapeutics | Travel · 2025-06-09 | Relizorb | $1,035 |
| Alcresta Therapeutics | Travel · 2025-06-09 | Relizorb | $352 |
See earlier years (2023, 2022)
2023: $118
| Takeda Pharmaceuticals U.S.A. | Gattex | $118 | 2 payments
|
2022: $2,800
| Takeda Pharmaceuticals U.S.A. | Gattex | $2,800 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Fresenius Kabi USA, LLC · A Multicenter, Prospective, Controlled, Longitudinal-Cohort Study Assessing the Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (Pnac) · 2022 | Their institution | $50,020 |
Professional record
- NPI
- 1649569245
- Licence
- CA A123822California A123822: Current · expires 2026-12-31
- Trained
- Pennsylvania State University College of Medicine, 2011
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 2080P0206X (2080P0206X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2011-04-04
- NPI last updated
- 2024-04-10
- NPI record certified
- 2024-04-10
This is when the NPI record was last certified, not a medical board exam.